Greetings

First of all, I would like to express my sincere thanks to the customers who have always trusted and accompanied inno.N during the past time. We are very grateful for that and will always strive to bring to inno.N's dear customers the best quality products to improve everyone's overall health.

The pharmaceutical industry is a high-tech industry that plays an important role in the development of a country. After first entering the pharmaceutical manufacturing field as a division of CJ Cheil Jedang in 1984, we took a new step forward in 2020 by changing our name to "inno.N" .

Over the past 40 years, inno.N has been on a creative and challenging journey. In 2019, inno.N launched the 30th drug developed and registered in Korea - K-CAB, and this is also a remarkable result of the R&D efforts that inno.N has achieved .

From those successes, inno.N continues to show the world the remarkable level of development of the Korean pharmaceutical industry by manufacturing and exporting pharmaceutical products applying advanced technologies.

Aside from the successes, inno.N has not forgotten its obligations as part of the community. ISO 37001 certification and application of ISO 37301 which is the global standard to root out corruption in business management while complying with the law is one of the innovative ways.N to ensure transparency in business its business activities.

inno.N will continue to work hard, not only in the research of new drugs and biologic drugs for the treatment of cancer, immune diseases, gastrointestinal diseases, infections and viral diseases, but also focus on protecting the latest technologies to bring customers the best products.

Finally, I would like to express my deepest gratitude to all of you for taking the time to visit our site!